GETT
17.5.2021 13:02:09 CEST | Business Wire | Press release
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is supporting the UK government Department for Transport and its Global Travel Taskforce with the safe return of international travel.
Gett’s ground transportation B2B marketplace now provides its clients with updates from the UK Government’s ‘traffic light’ system, supporting partners and users worldwide for the safe return of international travel. On its platform, Gett will update users with information on testing, quarantining, and travel restrictions to allow passengers access to information and government guidelines in relation to the next phase of re-opening the UK economy. This initiative supports Gett’s desire to assist employers to satisfy their duty of care obligations towards their employees, by providing users with access to information for safe travel.
As announced by the UK government on 9 April 2021, the ‘traffic light’ system applies different risk-based restrictions for passengers returning to the UK. Those travelling from ‘green’ countries require a negative Covid-19 test prior to departure but do not have to isolate when coming back into the UK, whilst travellers returning from ‘amber’ countries similarly require a negative pre-departure Covid-19, but also must isolate at home for 10 days upon their return and get a PCR test on days 2 and 8. Travellers from ‘red’ countries additionally require a negative Covid-19 test prior to departure and must isolate in specified hotels for 10 days.
Currently serving more than a quarter of Fortune 500 companies, Gett‘s unique position as a B2B marketplace for ground transportation management makes Gett a valuable partner for the UK government’s reopening of corporate travel. Gett has recently strengthened its international offering, with further expansion into the US market through the continued growth of global partner fleets. This includes the previously announced partnership with e-fleet operator Curb Mobility , joining a portfolio of existing corporate fleet, ride-hailing, taxi, and limo providers, including Lyft and Ola .
Andrew Verbitsky, Deputy CEO of Gett, commented: “The safe resumption of international travel is essential to restarting the corporate travel sector and supporting and enabling global economic recovery. Gett, as the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is uniquely positioned to be a valued partner in this important milestone for the UK and global economy. Gett is committed to the safe resumption of corporate travel for its B2B clients and their employees.”
About Gett
Gett is a technology platform solely focused on corporate Ground Transportation Management (GTM), a market worth $79.6B globally. https://bit.ly/2SEIV3M
Gett is the GTM category leader, serving over a quarter of the Fortune 500 companies.
Gett’s cloud-based software aggregates existing transportation providers onto a single platform, helping businesses manage all of their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally.
Gett organises corporate fleet, ride-hailing, taxi, and limo providers on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saving businesses time and money.
Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom